The Amschwand Sarcoma Cancer Foundation accepts both check and credit card donations.  Donations made by check may be mailed to 2260 West Holcombe, Suite 174, Houston, Texas  77030.  Arrangements to donate by credit card (MC, VISA, and AMEX) may be made by contacting ASCF at (832) 367-9474 (WISH).     

Also, please be sure to check with your employer to see if they sponsor a matching contributions program. Many companies will match the non-profit donations of their employees. Again, our deepest thanks.

Where Do Your Donations Go?

Since its inception, the Amschwand Sarcoma Cancer Foundation has provided direct support, temporary housing and information to thousands of patients across the United States while also increasing our community's awareness of the disease and the needs of those affected by it.  In addition to its own programs, ASCF has provided grant funding to the following organizations following a peer reviewed application process.

The University of Texas MD Anderson Cancer Center (MDACC) , Sarcoma Center

Patients at M. D. Anderson's Sarcoma Center have a five-year survival rate well above the national average, and an outstanding 80% rate for classical osteosarcoma. The center diagnoses, treats and manages sarcomas of the soft tissue and bone, using the latest technology available. Funds from ASCF's Physician Scientist Program provided to young researchers at MDACC have made a significant contribution toward improving the scientific understanding and development of new treatment modalities for Ewing's sarcoma, osteosarcomas, gastrointestinal stromal tumors (GIST), and rhabdomyosarcomas.  Even more, support from ASCF has been instrumental in helping these young researchers to secure additional research funding for sarcoma. “ The support of the Amschwand Sarcoma Cancer Foundation helped me get a $700,000 NIH grant for sarcoma research. You have my sincerest thanks,” said Dr. Jonathon C. Trent, Assistant Professor of Medicine, Department of Sarcoma Medical Oncology and just one of ASCF's many grant recipients at MDACC.

MD Anderson Children's Cancer Hospital

Pediatric sarcoma specialists at MD Anderson Children's Cancer Hospital provide treatments to and develop novel therapies for children and adolescents diagnosed with sarcoma cancers.  Under the leadership of Dr. Eugenie Kleinerman, MD Anderson's Children's Hospital has not only worked to identify new therapies for the treatment of sarcoma cancers but also new delivery vehicles that facilitate getting treatments to the right places with relative ease.  In fact, the aeresol therapies developed at Anderson's Children's Hospital are now becoming a standard of care for certain pediatric sarcoma patients with lung metastasis.  Past grant recipients at MD Anderson Children's Cancer Hospital include Dr. Nadia Koshkina and Dr. Andrea Hayes Jordan. 

Association of Cancer Online Resources (ACOR)

ACOR is a cancer information system that offers access to almost 200 electronic mailing lists and a variety of unique websites. The mailing lists are designed to be public online support groups providing information and community to tens of thousands of patients, caregivers, and people looking for answers about cancer, including those affected by sarcoma. In support of our mission which includes offering tangible support and education to patients and caregivers, ASCF funds have been earmarked to ensure that sarcoma-specific lists and resources provided by ACOR to patients and caregivers continue. 

Texas Children's Cancer Center (TCCC)

The Texas Children's Cancer Center is world renowned for its work in pediatric cancer and hematology disorders offering innovative therapies for all forms of childhood cancer including some sarcomas. Under the leadership of Dr. Marc Horowitz whose speciality is pediatric sarcoma, the Cancer Center works to improve patient outcomes for those affected by the disease while meeting children's other unique needs in a child-friendly setting.  Past TCCC grant recipients include Dr. Lisa Wang whose focus is on cancer predisposition syndromes, specifically Rothmund-Thomson syndrome, a rare inherited disorder in children that predisposes affected individuals to osteosarcoma.

Dana-Farber Cancer Institute, Sarcoma Treatment Center

The Center for Sarcoma and Bone Oncology at Dana Farber Cancer Institute has dedicated specialty expertise in the pathologic and radiologic assessment of sarcoma, the application of novel soft-tissue and bone reconstructive techniques permitting limb salvage, and access to the most promising new therapies for these malignancies. They are dedicated to identifying and developing cutting edge treatment strategies for both soft tissue and bone malignancies. Past ASCF funds have been earmarked for gastrointestinal stromal tumor research conducted under the supervision of Dr. George Demetri, M.D.

University of Texas Health Science Center San Antonio -- Cancer Therapy and Research Center (UTHCSSA - CTRC)

The University of Texas Health Science Center San Antonio (UTHSCSA) is nationally recognized institute of health science education and research.  In December 2007, its National Cancer Institute (NCI) designated Cancer Therapy and Researh Center (CTRC) officially became the hallmark of UTHSCSA's growing enterprise with is mission to promote interdisciplinary research in cancer related areas of basic science, clinical research, and cancer prevention and control, and to foster the application of the results of that research in the community.  

The CTRC's Institute for Drug Development (IDD) has long been internationally recognized for its work in conducting clinical research studies. In fact, fifteen of the cancer drugs most recently approved by the U.S. Food and Drug Administration underwent development and/or testing at the IDD in San Antonio.  As such, ASCF is optimistic that the CTRC's growing sarcoma center will benefit from some of the organization's past success in developing new approved therapies for other forms of cancer. 

Under the direction of Dr. Charles Keller, past ASCF funds have been earmarked for Platelet-derived growth factor receptor A research in Rhabdomyosarcoma (a form of sarcoma that arises in pediatric patients). 

Georgetown University Medical Center -- Lombardi Comprehensive Cancer Center

Using molecular and cell-based models, researchers at Georgetown University Medical Center have refined the picture of how a cancer-promoting protein associated with Ewing’s sarcoma functions. In the process, they have hit upon a possible strategy for treatment of this form of sarcoma, which although rare is highly malignant and most often strikes teens and young adults.  Dr. Jeffery Toretsky, ASCF grant reciptient and associate professor in the Departments of Oncology and Pediatrics at the Lombardi Comprehensive Cancer Center at Georgetown has been at the center of this groundbreaking research and continues to commit his time and resources toward finding treatments that work for Ewing's and other sarcoma patients. 

Georgetown University Medical Center has as its mission to seek to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. As one of only 39 designated NCI Comprehensive Cancer Centers in the country and the only one in our nation's capital, its internationally-renowned clinical team offers the latest treatments for virtually every type of cancer, with a particular emphasis in solid tumors as well as both adult and pediatric hematologic cancer.